These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 11001685)

  • 21. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy for patients with progressive Parkinson's disease].
    Murata M
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1432-7. PubMed ID: 13677891
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
    Molchadski I; Korczyn AD; Cohen OS; Katzav A; Nitzan Z; Chapman J; Hassin-Baer S
    Acta Neurol Scand; 2011 Feb; 123(2):117-21. PubMed ID: 21108621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.
    Sharma JC; Ross IN; Rascol O; Brooks D
    Eur J Neurol; 2008 May; 15(5):493-6. PubMed ID: 18355302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
    Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 28. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Rice JE; Antic R; Thompson PD
    Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatments for Parkinson's disease.
    Health News; 2000 Jun; 6(6):8. PubMed ID: 10865523
    [No Abstract]   [Full Text] [Related]  

  • 31. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Alves R; Barbosa E; Scaff M
    Mov Disord; 2006 Dec; 21(12):2267-8; author reply 2268. PubMed ID: 17078068
    [No Abstract]   [Full Text] [Related]  

  • 33. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
    Ghiglieri V; Picconi B; Calabresi P
    Mov Disord; 2010 Aug; 25(11):1527-9. PubMed ID: 20623774
    [No Abstract]   [Full Text] [Related]  

  • 34. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
    Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Merims D; Ziv I; Djaldetti R; Melamed E
    Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
    [No Abstract]   [Full Text] [Related]  

  • 37. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
    Zhao G; Li Y; Shao M; Ding Y
    Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):482-4. PubMed ID: 11829894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Nutt J
    Mov Disord; 1999; 14 Suppl 1():74. PubMed ID: 10493408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.